Herbert Irving Comprehensive Cancer Center
Investigator
Ran Reshef, MD
Phone
212-342-0530
Email
rr3036@cumc.columbia.edu
Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program (link is external) at Columbia, a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.

Dr. Reshef serves as Director of Translational Research for the Blood and Marrow Transplantation program and Clinical Lead for the CAR-T Cell Program. He joined Columbia University in 2015 after spending 8 years at the University of Pennsylvania where he conducted research in stem-cell transplantation and immunotherapy. Dr. Reshef primarily cares for patients with leukemia, MDS, lymphoma, myeloma and other blood cancers and he oversees the clinical trials offered to patients undergoing stem-cell transplantation. His research focuses on innovative ways to improve the outcome of patients undergoing stem-cell transplants and novel cell therapies. Dr. Reshef's research is funded by the National Cancer Institute, American Society of Clinical Oncology, National Marrow Donor Program and Department of Defense. He previously received awards from the Leukemia & Lymphoma Society and American Society of Hematology.

Clinical Studies Managed By This Investigator:
Condition Study Title
Transplant [ CLOSED ] A study for patients with acute graft host disease (GVHD) following bone marrow transplant using study drug Natalizumab
Stem Cell Transplant [ CLOSED ] A study for patients with chronic Graft Versus Host Disease (cGVHD) using study drug Ibrutinib
Blood Disorders [ CLOSED ] Study of Effects of Itacitinib in Combination with Corticosteroids for of Graft-Versus-Host Disease (GVHD) in Pregnant Partner
Lymphoma [ CLOSED ] Study of EBV-Cytotoxic T Lymphocytes (EBV-CTLs) in Patients with Epstein-Barr Virus-Associated Viremia or Malignancies
Cancer [ CLOSED ] Study of EBV-CTLs in Patients with Epstein-Barr Virus-Associated Viremia or Lymphoma
Lymphoma Study of Drug for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Stem Cell Transplant [ CLOSED ] Study of Drug for the Treatment of Cytomegalovirus (CMV) Infection in Stem Cell Transplant Recipients
Lymphoma [ CLOSED ] Study of Experimental Product (KTE-C19) in Subjects with Relapsed or Refractory Indolent non-Hodgkin B-Cell Lymphoma
Lymphoma [ CLOSED ] Study of Axicabtagene Ciloleucel in Combinataion with Utomilumab in Subjects with Refractory Large B-Cell Lymphoma
Multiple Myeloma Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)
Leukemia [ CLOSED ] Study of Vedolizumab in Subjects Undergoing Stem Cell Transplantation
Lymphoma [ CLOSED ] Safety and Efficacy of Axicabtagene Ciloleucel and Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma
Cancer [ CLOSED ] Study of T-Cells (IMA202-101) Given in Combination with Chemotherapy to Patients with Solid Tumors
Multiple Myeloma Study of PBCAR269A in Participants With Relapsed/Refractory Multiple Myeloma
Leukemia [ CLOSED ] Study of PBCAR20A in Participants with Relapsed/Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Cancer Safety Study of PBCAR0191 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma and r/r B-cell Acute Lymphoblastic Leukemia
Cancer [ CLOSED ] TCR-engineered T Cells in Solid Tumors With Focus on Non-small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC)
Cancer TCR-engineered T Cells in Solid Tumors (ACTengine)
Lymphoma [ CLOSED ] Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma (ZUMA-19)
Infectious Disease A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Multiple Myeloma Safety and Efficacy of Bb2121 (Ide-cel) Combinations in Patients with Multiple Myeloma (KarMMa-7)
Lymphoma Dose-escalation Safety Study of PBCAR19B in Participants With CD19-expressing Malignancies (Non Hodgkin Lymphoma)
Leukemia Study of TSC 100 & TSC 101 in Patients with Leukemia Undergoing Haploidentical Allogeneic Blood Stem Cell Transplantation (HCT)
Cancer ACCESS: Study of Donor Blood Stem Cell Transplant in Patients with Multiple Myeloma, Leukemia, or Lymphoma
Multiple Myeloma Study of VRd Followed by Cilta-cel vs. VRd Followed by Rd Therapy in Patients with Newly Diagnosed Multiple Myeloma
Lymphoma Study of TAK-007 in Patients with Non-Hodgkin Lymphoma
Stem Cell Transplant Long-Term Follow-up Study for Participants of Kite-Sponsored Gene-Modified Therapy Studies